International Journal of Medical Science and Pharmaceutical Research

Background/Aim

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis frequently associated with systemic inflammatory diseases, particularly inflammatory bowel disease and rheumatic disorders. Although rheumatoid arthritis (RA) is widely recognized as the most common rheumatic comorbidity, the prevalence of RA among patients with PG has not been systematically quantified. The aim of this artic was to systematically evaluate rheumatic diseases associated with PG and to estimate the pooled prevalence of rheumatoid arthritis through a meta-analysis of observational studies.

Material and methods

A systematic review was conducted according to the PRISMA 2020 statement. PubMed/MEDLINE, Embase, Web of Science, SciELO, and LILACS were searched from database inception through June 2026. Observational studies reporting rheumatic diseases in patients with PG were included, whereas case reports, reviews, and studies without extractable data were excluded. A random-effects meta-analysis of proportions was performed to estimate the pooled prevalence of RA.

Results

Seven observational studies comprising 529 patients with PG were included in the qualitative synthesis. Four studies involving 492 patients provided sufficient data for quantitative analysis. Rheumatoid arthritis was the most consistently reported rheumatic disease, whereas other inflammatory disorders—including seronegative arthritis, psoriatic arthritis, systemic lupus erythematosus, Behçet disease, systemic sclerosis, ANCA-associated vasculitis, and Takayasu arteritis—were identified less frequently and were reported inconsistently across studies. The pooled prevalence of RA was 11.9% (95% confidence interval [CI], 9.3%–15.1%). No statistical heterogeneity was detected (I² = 0%); however, this finding should be interpreted cautiously given the small number of studies included in the quantitative synthesis.

Conclusions

Rheumatoid arthritis is a frequent and consistent comorbidity in patients with PG, affecting approximately one in nine patients. Although additional rheumatic diseases have been described, current evidence remains insufficient for robust quantitative synthesis because of heterogeneous reporting. These findings support routine rheumatologic evaluation in patients with PG and reinforce the concept of PG as a systemic inflammatory disease with clinically relevant musculoskeletal involvement.

pyoderma gangrenosum; rheumatoid arthritis; neutrophilic dermatoses; rheumatic diseases; systematic review; meta-analysis.

1. Callen JP. Pyoderma gangrenosum. Lancet. 1998 Feb 21;351(9102):581-5. doi: 10.1016/S0140-6736(97)10187-8. PMID: 9492798.
2. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1008-17. doi: 10.1111/j.1468-3083.2009.03199.x. Epub 2009 Mar 11. PMID: 19470075.
3. Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015 Oct;73(4):691-8. doi: 10.1016/j.jaad.2015.06.021. Epub 2015 Aug 5. PMID: 26253362.
4. Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2017 Jun;18(3):355-372. doi: 10.1007/s40257-017-0251-7. PMID: 28224502.
5. Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen MC, Guenova E, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020 Oct 8;6(1):81. doi: 10.1038/s41572-020-0213-x. PMID: 33033263.
6. Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018 Apr 1;154(4):461-466. doi: 10.1001/jamadermatol.2017.5980. PMID: 29450466.
7. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002 Oct 31;347(18):1412-8. doi: 10.1056/NEJMoa013383. PMID: 12409543.
8. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012 Sep;132(9):2166-70. doi: 10.1038/jid.2012.130. Epub 2012 Apr 26. PMID: 22534879.
9. Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013 Sep 8;8:136. doi: 10.1186/1750-1172-8-136. PMID: 24010984; PMCID: PMC3844435.
10. Tan MG, Singh N, Kirshen C, Tolkachjov SN. Association between pyoderma gangrenosum and autoimmune connective tissue disorders: A systematic review. Int J Dermatol. 2024 Apr;63(4):e92-e94. doi: 10.1111/ijd.17088. Epub 2024 Feb 25. PMID: 38402537.
11. Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016 Nov;175(5):882-891. doi: 10.1111/bjd.14691. Epub 2016 Aug 23. PMID: 27106250.
12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.
13. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis. Adelaide: JBI; 2020. doi:10.46658/JBIMES-20-01. 
14. Ye MJ, Ye JM. Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management. Dermatol Res Pract. 2014;2014:461467. doi: 10.1155/2014/461467. Epub 2014 Oct 8. PMID: 25374597; PMCID: PMC4206920.
15. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011 Dec;165(6):1244-50. doi: 10.1111/j.1365-2133.2011.10565.x. PMID: 21824126.
16. Adışen E, Erduran F, Gürer MA. Pyoderma Gangrenosum: A Report of 27 Patients. Int J Low Extrem Wounds. 2016 Jun;15(2):148-54. doi: 10.1177/1534734616639172. Epub 2016 Mar 23. PMID: 27009790.
17. Bardazzi F, Maltoni L, Clarizio G, Baracca MF, Loi C, Starace M, et al. Pyoderma Gangrenosum: A Retrospective Case Series of 44 Patients. Dermatol Pract Concept. 2024 Oct 30;14(4):e2024265. doi: 10.5826/dpc.1404a265. PMID: 39652952; PMCID: PMC11620182.
18. Ramos-Rincón JM, Esteban-Jarabo J, Senent M, Belinchón-Romero I. Pyoderma Gangrenosum in Spain: Clinical Features, Therapeutic Management, and Outcomes in a 32-Patient Case Series. Health Sci Rep. 2025 Dec 18;8(12):e71537. doi: 10.1002/hsr2.71537. PMID: 41424671; PMCID: PMC12715351.
19. El Kassimi I, Rkiouak A, Sahel N, Zaizaa M, El Bougrini Z, Talamoussa B, et al. Systemic disease associations and management of pyoderma gangrenosum: a single-center retrospective case series. Eur J Med Case Rep. 2026;10(7):218-222. doi:10.24911/ejmcr.9-2648. 
20. Virkkala J, Polet S, Jokelainen J, Huilaja L, Sinikumpu SP. Clinical characteristics and comorbidities of the most common atypical wounds in Northern Finland in 1996-2019: A retrospective registry study. Health Sci Rep. 2022 Sep 26;5(5):e864. doi: 10.1002/hsr2.864. PMID: 36189416; PMCID: PMC9511497.
21. Marzano AV, Trevisan V, Lazzari R, Crosti C. Pyoderma gangrenosum: study of 21 patients and proposal of a 'clinicotherapeutic' classification. J Dermatolog Treat. 2011 Oct;22(5):254-60. doi: 10.3109/09546631003686069. Epub 2010 Jul 28. PMID: 20666672.
22. Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther. 2013 Oct 2;15(5):219. doi: 10.1186/ar4325. PMID: 24286137; PMCID: PMC3978765.
23. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965. PMID: 22150039.
24. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018 Jan;281(1):8-27. doi: 10.1111/imr.12621. PMID: 29247995; PMCID: PMC5756628.
25. Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol. 2022 Sep;23(5):615-634. doi: 10.1007/s40257-022-00699-8. Epub 2022 May 24. PMID: 35606650; PMCID: PMC9464730.
26. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006 Jul 22;333(7560):181-4. doi: 10.1136/bmj.333.7560.181. PMID: 16858047; PMCID: PMC1513476.
27. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006 Apr;55(4):505-9. doi: 10.1136/gut.2005.074815. Epub 2005 Sep 27. PMID: 16188920; PMCID: PMC1856164.
28. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996 Mar;34(3):395-409; quiz 410-2. doi: 10.1016/s0190-9622(96)90428-4. PMID: 8609250.
29. George C, Deroide F, Rustin M. Pyoderma gangrenosum - a guide to diagnosis and management . Clin Med (Lond). 2019 May;19(3):224-228. doi: 10.7861/clinmedicine.19-3-224. PMID: 31092515; PMCID: PMC6542232.